March 19, 2019 — Late-breaking results confirm the HeartFlow FFRct (fractional flow reservecomputed tomography) Analysis enables efficient identification of which patients, despite symptoms suggestive of coronary artery disease (CAD), have a low risk of adverse cardiovascular events and can safely avoid invasive testing out to one year. These results from the ADVANCE trial were presented as a late-breaking trial during theAmerican College of Cardiology’s (ACC)68th Annual Scientific Session, March 16-18 in New Orleans, and simultaneously published in theJournal of the American College of Cardiology (JACC): Cardiovascular Imaging.
In the ADVANCEstudy在超过5000名患者中，临床医生使用来自心脏流量分析的FFRct值来帮助确定患者发生不良心血管事件的风险，并决定管理计划。绝大多数心流分析结果为阴性的患者接受了药物治疗，而没有接受侵入性检测或治疗。一年后，这一组的患者心血管死亡或心脏病发作(心肌梗死)的比率明显较低(0.2%)。相比之下，在心流量分析阳性的患者中，心血管疾病死亡或心脏病发作的比率要高出四倍，其中许多患者需要侵入性治疗。这些结果表明，被确定为不良事件风险较低的患者可以单独使用药物进行安全治疗，并避免侵入性管理。重要的是，这些患者在90天内的血运重建率(支架或搭桥手术)很低，此后的血运重建率可以忽略不计。
“These findings provide reassurance regarding the safety of patient management utilizing an FFRct-guided decision pathway, particularly in lower-risk patients who did not undergo an invasive evaluation,” said Manesh Patel, M.D., FACC, chief, Division of Cardiology, Department of Medicine, Duke University School of Medicine, Duke University Health System. “By adding the HeartFlow FFRct to our available resources for diagnosing stable coronary disease, we are able to provide patients with better care as we efficiently evaluate risk in patients getting a coronary CTA, more precisely stratify patients and improve efficiency in the cath lab.”
心脏流动分析是一种无创的心脏测试，用于有稳定症状的CAD患者，CAD是世界范围内死亡的主要原因。Starting with a standardcoronary computed tomography angiogram (CTA)在美国，心脏流量分析系统会创建一个数字的、个性化的三维心脏模型，并提供沿冠状动脉的FFRct值。这些信息有助于医生评估血管阻塞可能对血流的影响，并为每个患者确定最佳治疗方案。FFRct值为阳性(≤0.80)表明冠状动脉阻塞阻碍血液流向心肌，可能需要有创性处理。
In the ADVANCE Registry, patients from the United States, Japan, Europe and Canada underwent a coronary CTA, and when additional information was needed, a HeartFlow Analysis was ordered. The added information contained in the HeartFlow Analysis led physicians to reconsider and change management plans for two-thirds of their patients. Some who were originally scheduled to receive a coronary stent or bypass operation were safely able to avoid the procedure and be treated with medications alone, while others who would have received medications were redirected to stenting or bypass surgery.
For more information:www.heartflow.com
August 10, 2022
